Jun. 2 at 12:11 AM
Attached is a history of what happened to the share prices of all 62 new commercial-stage oncology focused bios since 1/1/13.
18 of the 62 were acquired @ meaningful gains. 16 of the 18 (~90%) acquired at gains were acquired within 2 years of FDA approval. Even 1 of the 2 outliers (TSRO) was acquired within 2 years of its flagship's product approval, so we believe it is not truly an outlier. TSRO's 1st product was for nausea & never its priority.
9 of the 62 were sold @ losses for shareholders (versus its share price 2 days post FDA approval).
3 went bankrupt or were delisted. Last trades were for pennies a share.
32 are still independent. Only 7 pf these 32 still independent trade higher today than @ approval.
Double check our work for yourself. The evidence is overwhelming shareholder value of the bios in this peer group is maximized via M&A exit within 2 years of FDA approval. We're furious
$SNDX has not accepted INCY's latest offer
Others than should have sold?
$KPTI
$LEGN
$CHRS ?
$PBYI